L'éradication de la poliomyélite : Un défi à l'aube du XXI e siècle

Virologie

Volumn 2 AUG SUPPL., Issue , 1998, Pages 30-41

  Delpeyroux, F ^a   Crainic, R ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Enterovirus; Poliomyelitis; Poliovirus; Vaccine

Indexed keywords

ENTEROVIRUS; POLIOVIRUS;

EID: 0006949478     PISSN: 12678694     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Strebel PM Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992 ; 14 : 568-79.
2. Minor PD. The molecular biology of poliovaccines. J Gen Virol 1992 ; 73 : 3065-77.
3. Assembly WH. Forty-first world health assembly : global eradication of poliomyelitis by the year 2000. WHO, Geneva 1988.
4. Hull HF, Birmingham ME, Melgaard B, Lee JW. Progress toward global polio eradication. J Infect Dis 1997 ; 175 : S4-9.
5. Wimmer E, Hellen CUT, Cao XM. Genetics of poliovirus. Annu Rev Genet 1993 ; 27 : 353-436.
6. Minor PD. Poliovirus. In : N. Nathanson ed. Viral pathogenesis. Lippincott-Raven Publishers, Philadelphia 1997 ; 555-574.
7. Blondel B, Couderc T, Pavio N, Colbère-Garapin F. Biologie moléculaire du poliovirus. Ann Institut Pasteur/Actualités 1995 ; 6 : 86-99.
8. Racaniello VR. Early events in poliovirus infection - virus-receptor interactions. Proc Natl Acad Sci USA 1996 ; 93 : 11378-81.
9. Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 1985 ; 229 : 1358-65.
10. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus : molecular cloning, nucleotide sequence and expression of a new member of the immunoglobulin superfamily. Cell 1989 ; 56 : 855-65.
11. Flore O, Fricks CE, Filman DJ, Hogle JM. Conformational changes in poliovirus assembly and cell entry. In : J.M. Hogle ed. Seminars in virology, vol. 1. W.B. Saunders Co. 1990 : 429-38.
12. Pelletier J, Kaplan G, Racaniello VR, Sonenberg N. Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5′ non-coding region. Mol Cell Biol 1988 ; 8 : 1103-12.
13. Bodian D. Poliomyelitis : pathogenesis and histopathology. In : TM Rivas, FL. Horstall eds. Viral and rickettstal infectious of men. 3rd ed, Lippincott. Philadelphia, 1959 ; 479-98.
14. Sabin AB. Pathogenesis of poliomyelitis : reappraisal in the light of new data. Science 1956 ; 123 : 1151-7.
15. Freistadt MS, Eberle KE. Correlation between poliovirus type 1 Mahoney replication in blood cells and neuroviralence. J Virol 1996 ; 70 : 6486-92.
16. Couderc T, Barzu T, Horaud F, Crainic R. Poliovirus permissivity and specific receptor expression on human endothelial cells. Virology 1990 ; 174 : 95-102.
17. Ren RB, Racaniello VR. Pohovirus spreads from muscle to the central nervous system by neural pathways. J Infect Dis 1992 ; 166 : 747-52.
18. Couderc T, Christodoulou C, Kopecka H, et al. Molecular pathogenesis of neural lesions induced by poliovirus type 1. J Gen Virol 1986 ; 70 : 2907-18.
19. Dalakas MC. The post-polio syndrome as an evolved clinical entity. Definition and clinical description. Ann N Y Acad Sci 1995 ; 753 : 68-80.
20. Melnick JL. Enteroviruses : polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In : BN Fields, DM Knipe, PM Howley eds Fields virology, vol. 1. Raven publishers, Philadelphia, 1996 ; 655-712.
21. Salk JE. Consideration in the preparation and use of poliomyelitis virus vaccine. J Amer Med Ass 1955 ; 1548 : 1239-48.
22. Sabin A. Oral poliovirus vaccine : history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985 ; 151 : 420-36.
23. Ren R, Costantim F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor : a new model for poliomyelitis. Cell 1990 ; 63 : 353-62.
24. Strebel PM, Aubert-Combiescu A. Ion-Nedelcu N, et al. Paralytic poliomyelitis in Romania. 1984-1992. Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection. Am J Epidemiol 1994 ; 140 : 1111-24.
25. Toyoda H, Kohara M, Kataoka Y, et al. Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. J Mol Biol 1984 ; 174 : 561-85.
26. Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 1981 ; 214 : 916-9.
27. Kawamura N, Kohara M, Abe S, et al. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol 1989 ; 63 : 1302-9.
28. Ren R, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 1991 ; 65 : 1377-82.
29. Westrop GD, Wareham KA, Evans DMA, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 1989 ; 63 : 1338-44.
30. Haller AH, Stewart SR, Semler BL. Attenuation stem-loop lesions in the 5′ noncoding region of poliovirus RNA : neuronal cell-specific translation defects. J Virol 1996 ; 70 : 1467-74.
31. La Monica N, Racaniello VR. Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y. J Virol 1989 ; 63 : 2357-60.
32. Svitkin YV, Cammack N, Minor PD, Almond JW Translation deficiency of the Sabin type 3 poliovirus genome : association with an attenuating mutation C472 → U. Virology 1990 ; 175 : 103-9.
33. Macadam AJ, Pollard SR, Ferguson G, et al. Genetic basis of attenuation of the Sabin type-2 vaccine strain of poliovirus in primates. Virology 1993 ; 192 : 18-26.
34. Macadam AJ, Ferguson G, Arnold C, Minor PD. An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type-3 vaccine strain. J Virol 1991; 65 : 5225-31.
35. Bouchard MJ, Lam DH, Racaniello VR. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 1995 ; 69 : 4972-8.
36. Christodoulou C, Colbère-Garapin F, Macadam A, et al Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol 1990 ; 64 : 4922-9.
37. Horie H, Koike S, Kurata T, et al Transgenic mice carrying the human poliovirus receptor - new animal model for study of poliovirus neurovirulence. J Virol 1994 ; 68 : 681-8.
38. Georgescu MM, Balanant J, Macadam A, et al. Evolution of the Sabin type 1 poliovirus in humans : characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 1997 ; 71 : 7769-80
39. Tardy-Panit M, Blondel B, Martin A, Tekaia F, Horaud F, Delpeyroux F A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. J Virol 1993 ; 67 : 4630-8.
40. Equestre M, Genovese D, Cavalieri F, Fiore L, Santoro R, Perez-Bercoff R. Identification of a consistent pattern of mutations in neurovirulent variants derived from the Sabin vaccine strain of poliovirus type 2. J Virol 1991 ; 65: 2707-10.
41. Almond AJ, Westrop GD, Cann A, et al. Attenuation and reversion to neurovirulence of the Sabin poliovirus type-3 vaccine. In : A Lerner, RM Chanock. F Brown eds. Vaccines 85 Cold Spring Harbor laboratory. Cold Spring Harbor, 1985 ; 271-83.
42. Otelea D, Guillot S, Furione M, et al. Genomic modifications in naturally occuring neurovirulent revertants of Sabin 1 polioviruses. Dev Biol Stand 1993 ; 78 : 33-8
43. Dunn G, Begg NT, Cammack N, Minor PD. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol 1990 ; 32 : 92-5.
44. Contreras G, Dimock K, Furesz J, et al. Genetic characterization of Sabin type-1 and type-3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals 1992 ; 20 : 15-26.
45. Minor PD, Dunn G, Evans DMA, et al. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus : molecular and structural effects of a mutation in the capsid protein VP3. J Gen Virol 1989 ; 70 : 1117-23.
46. Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 1993 ; 196 : 199-208.
47. Georgescu MM, Tardy-Panit M, Guillot S, Crainic R, Delpeyroux F. Mapping of mutations contributing to the temperature sensitivity of the Sabin 1 vaccine strain of poliovirus. J Virol 1995 ; 69 : 5278-86.
48. Macadam AJ, Arnold C, Howlett J, et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 1989 ; 172 : 408-14.
49. Li J, Zhang LB, Yoneyama T, et al. Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients. Arch Virol 1996 ; 141 : 1047-54.
50. Lai MMC. RNA Recombination in animal and plant viruses. Microbiol Rev 1992 ; 56 : 61-79.
51. Cammack N, Phillips A, Dunn G, Patel V, Minor PD. Intertypic genomic rearrangements of poliovirus. strains in vaccinees. Virology 1988 ; 67 : 507-14.
52. Kew OM, Nottay BK. Evolution of the oral poliovaccine strains in humans occur by both mutation and intramolecular recombination. In : R. Chanock, R. Lerner eds. Modern approaches to vaccines. Cold Spring Harbor Press. NY, 1984 ; 357-67.
53. Lipskaya GY, Muzychenko AR, Kutitova OK, et al. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. J Med Virol 1991 ; 35 : 290-6.
54. Georgescu MM, Delpeyroux F, Crainic R. Tripartite genome organization of a natural type 2 vaccine nonvaccine recombinant poliovirus. J Gen Virol 1995 ; 76 : 2343-8.
55. Harber J, Bernhardt G, Lu HH, Sgro JY, Wimmer E. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor. Virology 1995 ; 214 : 559-70.
56. Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. J Infect Dis 1997 ; 175 : S286-92.
57. Alexander JP, Gary HE, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance - a review of the literature. J Infect Dis 1997 ; 175 : S176-82.
58. Hara M, Saito Y, Komatsu T. Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiol Immunol 1981 ; 25 : 905-13.
59. de Quadros CA, Hersh BS, Olive JM, Andrus JK, Dasilveira CM, Carrasco PA. Eradication of wild poliovirus from the Americas - acute flaccid paralysis surveillance. 1988-1995. J Infect Dis 1997 ; 175 : S37-42.
60. Nedelcu IN, Strebel PM, Toma F, et al. Sequential and combined use of inactivated and oral poliovirus vaccines - Dolj district. Romania, 1992-1994. J Infect Dis 1997 ; 175 : S241-S246.
61. Eichner E, Dietz K. Eradication of poliomyelitis : when can one be sure that polio virus transmission has been terminated ? Am J Epidemiol 1996 ; 143 : 816-22.
62. Tangermann RH, Costales M, Flavier J. Poliomyelitis eradication and its impact on primary health care in the Philippines. J Infect Dis 1997 ; 175 : S272-76
63. Anonymous. Factors affecting the immunogenicity of oral poliovirus vaccine : a prospective evaluation in Brazil and the Gambia. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. J Infect Dis 1995 ; 171 : 1097-106.
64. Georgescu MM, Delpeyroux F, Tardy-Panit M, et al. High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 1994 ; 68 : 8089-101.